Elutia outlines NXT-41X FDA submission this quarter, targeting Q2 2027 clearance

Intest projects Q4 revenue of $34M-$36M with gross margin of approximately 45% as record backlog builds into 2027

Atlassian tumbles after Q1 earnings but analysts maintain high ratings

Shoulder Innovations projects $68M-$70M 2026 net revenue as InSet Go launches and InSet Neo targets H1 2027 FDA submission

Top Midday Stories: October US Nonfarm Payrolls Rise More Than Expected; Investors Discuss Lower Anthropic IPO Value Than Original Estimate